Halozyme Therapeutics Inc (HALO)

[maumar]

2 upgrades right before the JPM conference. Is a buyout in the works? What kind of offer do you think Helen and the Board would accept? If they truly believe in the $1B in royalties projection, they should wait or take no less than $40 now, I would think.

Halozyme upgraded to Outperform from Market Perform at BMO Capital BMO Capital analyst Do Kim upgraded Halozyme Therapeutics to Outperform from Market Perform with a price target of $24, up from $17. The analyst expectx Darzalex and Perjeta/Herceptin approvals to help reverse the company's declining royalty revenues and return it to growth. In addition, the immediate restructuring after the PEGPH20 failure and prioritizing the "reliable" Enhanze business enable near-term profitability and sustainable positive cash flow, Kim tells investors in a research note.

Read more at:
https://thefly.com/landingPageNews.php?id=3015100